Elite Pharmaceuticals Inc (ELTP)

[ARbigguy1]

N2K, in support of controlling cost - "increase in gross margin is due to increased manufacturing efficiencies"
As stated in Elite's current report -
"Our gross profit margin was 49% during the three months ended September 30, 2020 as compared to 29% during the three months ended September 30, 2019. The increase in gross margin is due to increased manufacturing efficiencies of scale being achieved in relation to increased manufacturing volumes resulting in decreased unit overhead absorption rates, as compared to the comparable period of the prior year, combined with timing of in market sales by our marketing partner of the Amphetamine IR and Dantrolene products resulting in a higher level of related licensing fees during the three months ended September 30, 2020, as compared to the comparable period of the prior fiscal year."